

Provista

DIAGNOSTICS®

Precision Diagnostics to Enhance
Women's Health



Susan LaMacchia
Provista Diagnostics
PR@ProvistaDx.com
212-202-3174

Provista Diagnostics Appoints Judith K. Wolf, MD, as Chief Medical Officer

New York, NY – July 28, 2016 – Provista Diagnostics Inc., a company developing and commercializing protein-based diagnostic, prognostic and monitoring tests for cancers affecting women, has appointed Judith K. Wolf, MD, as Chief Medical Officer. In this role, Dr. Wolf will guide the continued clinical progress of the company’s flagship product Videssa® Breast. Dr. Wolf will also assist in overseeing Provista’s diagnostics pipeline and aid in the identification of new diagnostic approaches for development.

“I am excited to join the Provista team and look forward to using my clinical experience to further develop blood-based diagnostic tests,” said Judith K. Wolf, MD, Chief Medical Officer, Provista Diagnostics, Inc. “With Videssa Breast we have the ability to help physicians detect breast cancers at the earliest stage when treatment options are the most successful.”

Dr. Wolf joins Provista from Vermillion Inc. where she served as the Chief Medical Officer. She is a renowned expert in women’s health and diagnostics and is recognized for her work in the field of gynecologic cancers. She has co-authored almost 100 peer reviewed research articles and was the principle investigator or co-investigator for nearly 12 research grants related to gynecologic cancers. Dr. Wolf has also served as the principle investigator or collaborator on over 80 protocols and has presented at more than 50 conferences, numerous scientific exhibitions and seminars.

Dr. Wolf has been a professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center, and a clinical professor of the Division of Clinical Education at Arizona College of Osteopathic Medicine. Dr. Wolf is Chairman of the Medical and Scientific Advisory Board of the National Ovarian Cancer Coalition and a member of several gynecologic oncology organizations including; the American Association of Cancer Research, Felix Rutledge Society, Society of Gynecologic Oncology, American

Society of Clinical Oncology, and the American Gynecological and Obstetrical Society. Finally, she is a Fellow of the American College of Obstetrics and Gynecology.

“Dr. Wolf brings perspective and insights that fit perfectly with Provista’s work to advance the diagnostic technologies healthcare professionals need to provide their patients with reliable, high-confidence diagnoses in women’s cancers,” said David E. Reese, PhD, President and Chief Executive Officer, Provista Diagnostics, Inc. “The expertise she brings to our clinical development programs and our work to publish clinical research results will be invaluable to our efforts ahead.”

About Provista

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based proteomic diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistaDx.com

Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any

reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

###